REFERENCES
  1. Zhang J, Litvinova M, Wang W et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. The Lancet Infectious Diseases . 2020;20(7):793-802. doi:10.1016/s1473-3099(20)30230-9
  2. World Health Organization. Coronavirus disease (COVID-19) pandemic. 2020; https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 19 August, 2020.
  3. Coronavirus in Pakistan. Confirmed Cases. http://covid.gov.pk/. Accessed 27 August, 2020
  4. Diaz-Ballve L, Risso-Vasquez A, Rios F. Coronavirus disease 2019 (COVID-19) aspects of interest for critical care - narrative review.Rev Arg de Ter Int . 2020;Suppl 1:1-11.
  5. Qin C, Zhou L, Hu Z et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases . 2020;71(15):762-768. doi:10.1093/cid/ciaa248
  6. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci . 2020;57(6):389-399. doi:10.1080/10408363.2020.1770685
  7. Feng X, Li S, Sun Q et al. Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis. Front Med (Lausanne) . 2020;7:Article 301. doi:10.3389/fmed.2020.00301
  8. Xia X, Wen M, Zhan S, He J, Chen W. [An increased neutrophil/lymphocyte ratio is an early warning signal of severe COVID-19]. Nan Fang Yi Ke Da Xue Xue Bao [Journal of Southern Medical University] . 2020;40(3):333-336. doi:10.12122/j.issn.1673-4254.2020.03.06
  9. Yang A, Liu J, Tao W, Li H. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol . 2020;84:106504. doi:10.1016/j.intimp.2020.106504
  10. Liu Y, Du X, Chen J et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect . 2020;81(1):e6-e12. doi:10.1016/j.jinf.2020.04.002
  11. Ye W, Chen G, Li X et al. Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19. Respir Res . 2020;21(1):169. doi:10.1186/s12931-020-01428-7
  12. Ciccullo A, Borghetti A, Zileri Dal Verme L et al. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents . 2020;56(2):106017. doi:10.1016/j.ijantimicag.2020.106017
  13. Li H, Zhao M, Xu Y. [Biochemical analysis between common type and critical type of COVID-19 and clinical value of neutrophil/lymphocyte ratio]. Zhejiang da xue xue bao. Yi xue ban [Journal of Zhejiang University. Medical Sciences]. 2020 May;40(7):965-971.
  14. National Institute of Health (NIH), Islamic Republic of Pakistan. COVID-19. https://www.nih.org.pk/novel-coranavirus-2019-ncov/. Accessed March 27, 2020.
  15. Mercier J, Voutsadakis I. The platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer. J Gastrointest Oncol . 2018;9(3):478-486. doi:10.21037/jgo.2018.03.13
  16. Yeo A, Henningham A, Fantino E et al. Increased susceptibility of airway epithelial cells from ataxia-telangiectasia to S. pneumoniae infection due to oxidative damage and impaired innate immunity. Sci Rep . 2019;9(2627):1-10. doi:10.1038/s41598-019-38901-3
  17. Soylu K, Gedikli Ö, Ekşi A et al. Neutrophil-to-lymphocyte ratio for the assessment of hospital mortality in patients with acute pulmonary embolism. Archives of Medical Science . 2016;12(1):95-100. doi:10.5114/aoms.2016.57585
  18. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol . 2017;39(5):529-539. doi:10.1007/s00281-017-0629-x
  19. Zeiser R, Socié G, Blazar B. Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. Br J Haematol . 2016;175(2):191-207. doi:10.1111/bjh.14295
  20. Yang Y, Shen C, Li J et al. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. MedRxiv . 2020;[Preprint]. doi:10.1101/2020.03.02.20029975
  21. Meo SA, Alhowikan AM, Al-Khlaiwi T, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012-2019. doi:10.26355/eurrev_202002_20379
  22. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020;133(9):1015-1024. doi:10.1097/CM9.0000000000000722
  23. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med.2020;382(13):1199-1207. doi:10.1056/NEJMoa2001316